scispace - formally typeset
Y

Yu-Yan Tan

Researcher at Shanghai Jiao Tong University

Publications -  48
Citations -  903

Yu-Yan Tan is an academic researcher from Shanghai Jiao Tong University. The author has contributed to research in topics: Medicine & Disease. The author has an hindex of 14, co-authored 36 publications receiving 646 citations.

Papers
More filters
Journal ArticleDOI

Methylation of α-synuclein and leucine-rich repeat kinase 2 in leukocyte DNA of Parkinson's disease patients.

TL;DR: The results indicated that the methylation level of SNCA CpG-2, especially that of the 2nd, 4th and 9th C pG sites in leukocytes might have great potential to be a useful and informative biomarker in PD diagnosis and treatment.
Journal ArticleDOI

Curcumin inhibition of JNKs prevents dopaminergic neuronal loss in a mouse model of Parkinson’s disease through suppressing mitochondria dysfunction

TL;DR: The experiments demonstrated that curcumin can prevent nigrostriatal degeneration by inhibiting the dysfunction of mitochondrial through suppressing hyperphosphorylation of JNKs induced by MPTP, and suggested that JNK/mitochondria pathway may be a novel target in the treatment of PD patients.
Journal ArticleDOI

Amyloid-beta1-42 induces reactive oxygen species-mediated autophagic cell death in U87 and SH-SY5Y cells

TL;DR: It is shown that Abeta1-42 triggered autophagic cell death in both human glioma cell line (U87 cell) and human neuroblastoma cell lines (SH-SY5Y cell), which provides further insights into the mechanisms underlying Abeta-induced cytotoxicity.
Journal ArticleDOI

Freezing of Gait in Parkinson's Disease: Pathophysiology, Risk Factors and Treatments

TL;DR: Several risk factors of FOG have been identified, but need combinatorial optimization for predicting FOG more precisely and firm conclusions cannot be drawn on therapeutic efficacy, although the literature suggested that some therapeutic strategies showed promise.
Journal ArticleDOI

Economic burden of Parkinson's disease in a developing country: a retrospective cost analysis in Shanghai, China.

TL;DR: Total cost was significantly associated with the disease severity and the frequency of outpatient visits, and levodopa equivalent dose and the number of drugs being taken were also closely related with the drug cost.